RARE DISEASERESEARCH ATLAS

ORPHA:319189

Familial cortical myoclonus

high confidenceDisorder

Publications

151

58.8th percentile

Trials

1

Interventional, condition-specific

Researchers

825

Distinct authors in sample

Gene link

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Familial cortical myoclonus is a rare, genetic movement disorder characterized by , adult-onset, slowly , multifocal, cortical myoclonus. Patients present somatosensory-evoked, brief, jerky, involuntary movements in the face, arms and legs, associated in most cases with sustained, multiple, sudden falls without loss of consciousness. or other neurological deficits, aside from mild cerebellar late in the course of the illness, are absent.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

familial cortical myoclonus · familial myoclonus · myoclonus, familial cortical

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    151 matched papers (66 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    1 matched on ClinicalTrials.gov (1 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

151

151 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

151 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

66 in the last 10 years · high confidence · 58.8th percentile (publications denominator)

Phrase hits: 151 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

825

Distinct author names in 151 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Ikeda A16 papers · 2026

    Department of Epilepsy, Movement disorders and Physiology, Kyoto University Graduate School of medicine.

    Papers in Europe PMC
  2. 02
    Kobayashi K13 papers · 2026

    Department of Neurology, Kyoto University Graduate School of medicine.

    Papers in Europe PMC
  3. 03
    Hitomi T12 papers · 2026

    Department of Neurology, Kyoto University School of Medicine, Kyoto, Japan.

    Papers in Europe PMC
  4. 04
    Takahashi R12 papers · 2026

    Department of Neurology, Kyoto University Graduate School of medicine.

    Papers in Europe PMC
  5. 05
    Tsuji S9 papers · 2026

    Department of Molecular Neurology, The University of Tokyo Hospital, Tokyo, Japan.

    Papers in Europe PMC
  6. 06
    Matsumoto R8 papers · 2026

    Department of Epilepsy, Movement disorders and Physiology, Kyoto University Graduate School of medicine.

    Papers in Europe PMC
  7. 07
    Matsuhashi M7 papers · 2026

    Human Brain Research Center, Kyoto University Graduate School of Medicine, Japan.

    Papers in Europe PMC
  8. 08
    Tojima M7 papers · 2026

    Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

    Papers in Europe PMC
  9. 09
    Ishiura H5 papers · 2026

    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

    Papers in Europe PMC
  10. 10
    Neshige S5 papers · 2026

    Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

1

interventional trials for this specific condition

1 interventional trial matched this specific condition name; 1 currently recruiting in our sample.

Data as of 27 July 2026

1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).

high confidence · 76.8th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

1 interventional trials matched after quoted-phrase search and title/condition post-filter.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Familial cortical myoclonus" OR "familial myoclonus" OR "myoclonus, familial cortical"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Familial cortical myoclonus" OR "familial myoclonus" OR "myoclonus, familial cortical"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T13:17:52.420Z